scholarly journals Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway

2019 ◽  
Vol 8 (10) ◽  
pp. 4836-4844 ◽  
Author(s):  
Hao Jiang ◽  
Qian‐Qian Shi ◽  
Li‐Yuan Ge ◽  
Qian‐Feng Zhuang ◽  
Dong Xue ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mtor Pathway ◽  
Selenoprotein M

scholarly journals Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma

2008 ◽  
Vol 98 (5) ◽  
pp. 931-940 ◽  
Author(s):  
L Campbell ◽  
B Jasani ◽  
K Edwards ◽  
M Gumbleton ◽  
D F R Griffiths
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Disease Free Survival ◽  
Mtor Pathway ◽  
Free Survival ◽  
Caveolin 1 ◽  
Disease Free

Effects of betulinic acid on AKT/mTOR pathway in renal cell carcinoma

2022 ◽  
Vol 48 (1) ◽  
pp. 58-63
Author(s):  
Merve Nur Ataş ◽  
◽  
Barış Ertuğrul ◽  
Elif Sinem İplik ◽  
Bedia Çakmakoğlu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Betulinic Acid ◽  
Renal Cell ◽  
Mtor Pathway

Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma

2020 ◽  
Vol 489 ◽  
pp. 135-143 ◽  
Author(s):  
Antonios N. Gargalionis ◽  
Eleni Sarlani ◽  
Anastasios Stofas ◽  
Lina S. Malakou ◽  
Christos Adamopoulos ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mtor Pathway

mTOR pathway inhibition in renal cell carcinoma

2012 ◽  
Vol 30 (4) ◽  
pp. 356-361 ◽  
Author(s):  
Alvaro Pinto Marín ◽  
Andrés Redondo Sánchez ◽  
Enrique Espinosa Arranz ◽  
Pilar Zamora Auñón ◽  
Beatriz Castelo Fernández ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mtor Pathway ◽  
Pathway Inhibition

Impact of clinicopathological variables on mTOR Pathway activation in primary renal cell carcinoma (RCC) and matched metastases

2010 ◽  
Vol 211 (3) ◽  
pp. S129
Author(s):  
Alexander Kutikov ◽  
Zachary Piotrowski ◽  
Brian L. Egleston ◽  
Min Huang ◽  
Tahseen Al-Saleem ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mtor Pathway ◽  
Primary Renal Cell Carcinoma ◽  
Pathway Activation ◽  
Clinicopathological Variables

scholarly journals RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma

2014 ◽  
Vol 13 (1) ◽  
pp. 130-137 ◽  
Author(s):  
Sumanta K. Pal ◽  
Miaoling He ◽  
Tommy Tong ◽  
Huiqing Wu ◽  
Xueli Liu ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Aurora Kinase ◽  
Mtor Pathway ◽  
Rna Seq ◽  
Pathway Activation

Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 406-406
Author(s):  
Samuel D. Kaffenberger ◽  
Giovanni Ciriello ◽  
Andrew G. Winer ◽  
Martin Henner Voss ◽  
Jodi Kathleen Maranchie ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
External Validation ◽  
Mtor Pathway ◽  
The Cancer Genome Atlas ◽  
Genomic Alterations ◽  
Cell Renal Cell Carcinoma ◽  
Cluster 2

406 Background: Proteomics represents the ultimate convergence of DNA and expression alterations. We therefore sought to leverage TCGA reverse phase protein array (RPPA) data with an independent proteomic platform to identify druggable targets and pathways associated with prognosis in clear cell renal cell carcinoma (ccRCC). Methods: Unsupervised hierarchical consensus clustering was performed and differentially expressed proteins were identified for pathway analysis. Associations with clinicogenomic factors were assessed and Cox proportional hazards models were performed for disease-specific survival (DSS). Results: RPPA clustering of 324 patients from the ccRCC TCGA revealed 5 robust clusters characterized by alterations in specific pathways and divergent prognoses. Cluster 1 was characterized by poor DSS, decreased expression of receptor tyrosine kinases (RTK) and upregulation of the mTOR pathway. It was also associated with mTOR pathway genomic alterations, sarcomatoid histology and the ccb prognostic mRNA signature (all p<0.001). Cluster 2 was characterized by increased expression of RTKs and interestingly, had upregulation of the mTOR pathway with excellent DSS. After accounting for stage and grade, cluster designation remained independently associated with DSS (HR 0.23 for cluster 2, 95% CI 0.08-0.68; p=0.008). External validation was performed on a separate cohort of 189 patients with a different quantitative proteomics platform. A panel of phosphoproteins (pHER1, pHER2, pHER3, pSHC, pMEK, pAKT), highly discriminant between the most divergent RPPA clusters (1 and 2) was evaluated. Those at the highest quartile of activation in > 3 proteins were associated with improved DSS (HR 0.19, 95% CI 0.05-0.082; p=0.03). Patients with mTOR pathway activation segregated to those with coincident RTK activation (n=83) and those without (n=13). Conclusions: We have identified and validated proteomic signatures which cluster ccRCC patients into 5 prognostic groups. Furthermore, two distinct mTOR-activated clusters—one with high RTK activity and one with increased mTOR pathway genomic alterations were revealed, which may have prognostic and therapeutic implications.

scholarly journals Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk

2013 ◽  
Vol 105 (6) ◽  
pp. 424-432 ◽  
Author(s):  
Xiang Shu ◽  
Jie Lin ◽  
Christopher G. Wood ◽  
Nizar M. Tannir ◽  
Xifeng Wu
Keyword(s):  
Renal Cell Carcinoma ◽  
Energy Balance ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mtor Pathway ◽  
Carcinoma Risk

Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome

2020 ◽  
Vol 33 (12) ◽  
pp. 2580-2590
Author(s):  
Juan María Roldan-Romero ◽  
María Santos ◽  
Javier Lanillos ◽  
Eduardo Caleiras ◽  
Georgia Anguera ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Molecular Characterization ◽  
Renal Cell ◽  
Mtor Pathway ◽  
Chromophobe Renal Cell Carcinoma ◽  
Poor Outcome

mTOR Pathway in Renal Cell Carcinoma

2016 ◽  
pp. 417-428
Author(s):  
Matteo Santoni ◽  
Francesco Massari
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Mtor Pathway
Sign in / Sign up

Export Citation Format

Share Document